文献速递焦虑、强迫与应激相关障碍

神经可塑性药物TSND-201治疗PTSD的疗效与安全性随机临床试验

Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2026-01-01

该2期多中心双盲安慰剂对照10周随机临床试验纳入65例成人PTSD患者,评估TSND-201(甲基酮)每周口服4次(150mg后100mg)的疗效与安全性。

要点

  • PCL-5、SDS和MADRS评分亦显著改善,支持多维症状获益。
  • 常见不良事件包括头痛、食欲下降、恶心、头晕、血压升高、口干和失眠。

核心结论

  • TSND-201在成人PTSD患者中显示出统计学显著的疗效且耐受性良好,支持其作为快速起效、持久治疗PTSD的潜力。

研究设计与样本

  • IMPACT-1 B部分为2期、多中心、双盲、安慰剂对照、10周随机临床试验,2023年11月29日至2025年2月19日在美国、英国和爱尔兰16个中心开展,纳入65例18至65岁符合DSM-5当前PTSD诊断且症状持续6个月以上(CAPS-5≥35)的成人。

主要发现

  • PCL-5评分变化TSND-201组-28.46 vs 安慰剂组-19.47(LS治疗差-8.99,90%CI -17.81至-0.17)。
  • SDS评分变化TSND-201组-8.29 vs 安慰剂组-3.57(LS治疗差-4.72,90%CI -8.84至-0.61)。
  • MADRS评分变化TSND-201组-13.94 vs 安慰剂组-7.73(LS治疗差-6.21,90%CI -12.41至-0.27)。
  • TSND-201组常见治疗中出现的不良事件包括头痛、食欲下降、恶心、头晕、血压升高、口干和失眠。

关键数值与推荐

  • 主要终点为CAPS-5总分从基线至第64天的变化。
  • 次要终点包括PCL-5、SDS和MADRS评分变化。
  • 其他指标包括应答(较基线改善≥50%)、缓解(总分≤11)、丧失PTSD诊断、CAPS-5症状簇变化及治疗中出现的不良事件发生率。

临床怎么用

  • TSND-201每周口服4次(150mg后100mg)不联合心理治疗, dosing sessions由精神卫生专业人员以非指导性方式监护。
  • 治疗期间需监测不良事件、生命体征和哥伦比亚自杀严重程度评定量表。

局限性

  • 原文未报告样本量计算的细节及研究局限性讨论。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The phase 2 data presented here support the development of TSND-201 for posttraumatic stress disorder (PTSD), a disorder for which there is a significant unmet need for rapid-acting and effective treatments. TSND-201 (methylone) is a highly selective, rapid-acting neuroplastogen that releases serotonin, norepinephrine, and dopamine without direct activity at 5-hydroxytryptamine (5-HT) 2A receptors that has shown rapid, robust, and long-lasting benefit for preclinical PTSD-related behaviors and has been well tolerated in phase 1 studies of healthy volunteers. OBJECTIVE: To evaluate the efficacy and safety of TSND-201 vs placebo in adults with PTSD. DESIGN, SETTING, PARTICIPANTS: A Study to Assess the Use of Methylone in the Treatment of PTSD (IMPACT-1) part B was a phase 2, multicenter, double-blind, placebo-controlled, 10-week randomized clinical trial of TSND-201 in people with PTSD conducted between November 29, 2023, and February 19, 2025, across 16 sites in the US, UK, and Ireland. Adults aged 18 to 65 years who met DSM-5 criteria for current PTSD and 6 months or more of symptoms (Clinician-Administered PTSD Scales for DSM-5 [CAPS-5] ≥35) were eligible. INTERVENTIONS: Participants were randomized 1:1 to receive TSND-201 or placebo. There were 4 once-weekly oral dosing sessions (150 mg followed by 100 mg or placebo). No psychotherapy was provided; however, dosing sessions were monitored by mental health professionals using a nondirective approach. Participants were followed up for 6 weeks after the last dose. MAIN OUTCOMES AND MEASURES: The primary end point was change from baseline to day 64 in the CAPS-5 total severity score. Secondary end points included changes in PTSD Checklist for DSM-5 (PCL-5), Sheehan Disability Scale (SDS), and Montgomery-Åsberg Depression Rating Scale (MADRS) scores. Other measures included response (≥50% improvement from baseline), remission (≤11 total severity score), loss of PTSD diagnosis, changes in CAPS-5 symptom clusters, and incidence of treatment-emergent adverse events (TEAEs). Safety was assessed by monitoring adverse events, vital signs, and Columbia-Suicide Severity Rating Scale. RESULTS: Among the 65 participants (mean [SD] age, 43.7 [10.5] years; 39 female [60.0%]), TSND-201 demonstrated significantly greater improvement in CAPS-5 total score than placebo (least-squares mean difference, 9.64; 90% CI, -16.48 to -2.80; P = .01). PCL-5 (-28.46 vs -19.47; LS mean treatment difference, -8.99; 90% CI, -17.81 to -0.17), SDS (-8.29 vs -3.57; LS mean treatment difference, -4.72; 90% CI, -8.84 to -0.61), and MADRS (-13.94 vs -7.73; LS mean treatment difference, -6.21; 90% CI, -12.41 to -0.27) scores were also improved. Common TEAEs in the TSND-201 group included headache, decreased appetite, nausea, dizziness, blood pressure increased, dry mouth, insomnia. CONCLUSIONS AND RELEVANCE: Results of this randomized clinical trial reveal that TSND-201 demonstrated statistically significant efficacy and was well tolerated, supporting its potential as a rapid-acting, durable treatment for PTSD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05741710.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Jones A, Warner-Schmidt J, Kwak H, et al. Efficacy and Safety of the Neuroplastogen TSND-201 for the Treatment of PTSD: A Randomized Clinical Trial. JAMA Psychiatry. 2026. PMID: 41706459. doi:10.1001/jamapsychiatry.2025.4625

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。